Visiopharm

Private

HørsholmHealthcare & Life Scienceshttps://visiopharm.com/

Last Round

VC Round

Sep 1, 2020

Company Overview

Visiopharm is a decision/risk analysis company that provides AI-driven precision pathology software for research and diagnostics.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Medical AI, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Government Contracts, Usage-Based SaaS

AI Layer

Application

Keywords

precision pathologydigital pathologytissue image analysiscomputational pathologypathology AIdiagnostic decision supportimage analysis softwarequantitative pathologybiomarker quantificationcancer diagnosticsspatial biologydrug development supportCE-IVDR certifiedclinical trials supportmultiplexed image analysisTissue Micro Array analysis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Visiopharm Comparables

Compare Visiopharm with similar companies based on industry and business-model similarity.

Visiopharm comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Deciphex	87%
Indica Labs	85%
Aiforia	82%

View all Comparables

Visiopharm Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
VC Round	Sep 1, 2020
VC Round	Aug 24, 2018
Private Equity	Oct 5, 2007

View all Funding Rounds

Key People

Founding team and executive leadership

Michael Grunkin - Quantitative Digital Pathology

CEO

Executive Team

Christian Kaltoft

Chief Operating Officer

Executive Team

Visiopharm Investors

Notable investors and investment history

Visiopharm investors
Investor	Rounds
BankInvest	VC Round
Northcap Partners	VC Round, Private Equity
The Export and Investment Fund of Denmark	VC Round
ATP	VC Round
C.L. Davids Fond og Samling	VC Round

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Nov 8, 2025
Monthly visitors increased 106% MoM, reaching 9K.
May 3, 2025
Monthly visitors increased 59% MoM, reaching 5.9K.

View all signals

Visiopharm Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Visiopharm Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Visiopharm's valuation, stock price, and market status.

Firmographic Details

HeadquartersHørsholm

Employee Range90

Year Founded2002

Last FundingSep 1, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.